References
1. Piperno A, Alessio M. 2018. Aceruloplasminemia: Waiting for an
Efficient Therapy. Front Neurosci.12:1–8.
2. Marchi G, Busti F, Zidanes AL, et al . 2019. Aceruloplasminemia: A
severe neurodegenerative disorder deserving an early diagnosis. Front.
Neurosci..13:1–8.
3. Doyle A, Rusli F, Bhathal P . 2015. Aceruloplasminaemia:A rare but
important cause of iron overload. BMJ Case Rep:1–4.
4. Yamamura A, Kikukawa Y, Tokunaga K, et al . 1905–1910. Pancytopenia
and myelodysplastic changes in aceruloplasminemia: A case with a novel
pathogenic variant in the ceruloplasmin gene. Intern Med 2018. 57:.
5. Miyajima H, Hosoi Y . Aceruloplasminemia Summary Genetic counseling.
University of Washington, Seattle.2019.
6. Hayashida M, Hashioka S, Miki H, et al . 2016. Aceruloplasminemia
with psychomotor excitement and neurological sign was improved by
minocycline (Case Report). Med (United States). 95:1–7.
7. Miyajima H . 2015. Aceruloplasminemia. Neuropathology. 35:83–90.
8. Roberti M do RF, Filho HMB, Gonçalves CH, Lima FL . 2011.
Aceruloplasminemia: A rare disease - diagnosis and treatment of two
cases. Rev Bras Hematol Hemoter. 33:389–392.
9. Watanabe M, Ohyama K, Suzuki M, et al . 2018. Aceruloplasminemia with
abnormal compound heterozygous mutations developed neurological
dysfunction during phlebotomy therapy. Intern Med. 57:2713–2718.
10. Tai M, Matsuhashi N, Ichii O, et al . 2014. Case of presymptomatic
aceruloplasminemia treated with deferasirox. Hepatol Res. 44:1253–1258.
11. Vroegindeweij LHP, Langendonk JG, Langeveld M, et al . 2017. New
insights in the neurological phenotype of aceruloplasminemia in
Caucasian patients. Park Relat Disord. 36:33–40.